Literature DB >> 22204816

Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.

Paramita Baruah1, Michael Lee, Tunde Odutoye, Peter Williamson, Nicholas Hyde, Juan Carlos Kaski, Ingrid E Dumitriu.   

Abstract

BACKGROUND AND AIM: Head and neck cancers (HNC) are aggressive tumours. Tumour-specific T cells are frequently identified in patients with cancer, although they fail to control tumour progression. A family of proteins called co-stimulatory receptors regulate the function of T cells and may account for T cell dysfunction in cancer. Our aim was to characterise co-stimulatory receptors on T cells in HNC patients to identify novel targets for immunotherapy.
METHODS: Peripheral blood mononuclear cells were isolated from HNC patients and healthy controls and the expression of co-stimulatory (OX40, 4-1BB, ICOS) and co-inhibitory (CTLA-4, PD1) receptors was analysed on CD4(+) and CD8(+) T cells using flow cytometry.
RESULTS: We found that the levels of co-stimulatory receptors OX40 and 4-1BB were significantly lower on CD4(+) T cells from HNC patients. This was more pronounced in locally advanced tumours (T3/T4) compared to early carcinomas (T1/T2). PD-1 levels were higher on CD8(+) T cells in HNC patients compared to controls. Human papilloma virus (HPV)-specific CD8(+) T cells appeared to be more affected than Influenza-specific T cells.
CONCLUSIONS: Our results indicate that expression of co-stimulatory receptors on T cells from HNC patients is imbalanced with a preponderance of inhibitory signals, and reduction of stimulatory signals, especially in advanced disease. Restoring this balance could improve T cell therapy outcomes in HNC.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22204816     DOI: 10.1016/j.imbio.2011.11.005

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  24 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

Review 2.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 3.  Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Authors:  Jessica M Moskovitz; Jennifer Moy; Tanguy Y Seiwert; Robert L Ferris
Journal:  Oncologist       Date:  2017-05-15

Review 4.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

Review 5.  Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.

Authors:  Jennifer D Moy; Jessica M Moskovitz; Robert L Ferris
Journal:  Eur J Cancer       Date:  2017-03-18       Impact factor: 9.162

Review 6.  Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.

Authors:  Julie E Bauman; Robert L Ferris
Journal:  Cancer       Date:  2013-11-12       Impact factor: 6.860

7.  Serum Levels of OX40 in Early and Late-Stage Oral Squamous Cell Carcinoma.

Authors:  Aliya I Sani; Zil E Rubab; Shumaila Usman; Syed Zaryab Ahmed; Mervyn Hosein; Moazzam A Shahid
Journal:  Cureus       Date:  2021-04-20

Review 8.  Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.

Authors:  Ramez Philips; Chihun Han; Brian Swendseid; Joseph Curry; Athanassios Argiris; Adam Luginbuhl; Jennifer Johnson
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.

Authors:  Julie E Bauman; Jonathan Harris; Ravindra Uppaluri; Min Yao; Robert L Ferris; Josephine Chen; Richard C Jordan; Nikhil P Joshi; Srinivas Jujjuvaparu; Dukagjin M Blakaj; Christina Henson; Jawad Sheqwara; Loren K Mell; Neilayan Sen; David A Clump; Madhur K Garg; Emrullah Yilmaz; Pedro Torres-Saavedra; Quynh-Thu Le
Journal:  Cancers (Basel)       Date:  2021-06-09       Impact factor: 6.639

Review 10.  Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.

Authors:  Janice L Farlow; J Chad Brenner; Yu L Lei; Steven B Chinn
Journal:  Oral Oncol       Date:  2021-07-01       Impact factor: 5.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.